Cue Biopharma, Inc. cotiza a 19.92 USD y tiene una capitalización bursátil de $145M. En los últimos 12 meses ha facturado $38M con un margen de flujo de caja libre del -79.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, w…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-1.08 | $0.30 | $-2.10 | $-2.70 |
| Estimado | $-3.30 | $-2.70 | $-2.55 | $-3.90 |
| Sorpresa | +67.3% | +111.1% | +17.6% | +30.8% |
| Métrica | CUE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -96.7% | -38.6% | -58.1% |
| Net Margin | -96.8% | -33.6% | -63.3% |
| FCF Margin | -79.6% | -13.9% | -65.7% |
| ROE | -100.6% | -40.4% | -60.2% |
| ROA | -63.0% | -32.0% | -31.0% |
| Current Ratio | 2.74 | 2.84 | -0.10 |
| Debt / Equity | — | 0.28 | — |